Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
24 sept. 2024 16h20 HE
|
Kairos Pharma, Ltd.
LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health...